Oculis AG(US:OCS) Newsfilter·2025-04-01 08:00Core Insights - Oculis Holding AG will host an R&D Day on April 15, 2025, to provide updates on its clinical candidates and business strategy [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema (DME), Licaminlimab for dry eye disease (DED), and Privosegtor for acute optic neuritis [16] Clinical Development Updates - The R&D Day will feature updates on the Phase 3 DIAMOND trials for OCS-01, the development plan for Licaminlimab in DED, and the expanded data analysis from the ACUITY Phase 2 trial for Privosegtor [2][3] - OCS-01 is a high concentration dexamethasone eye drop aimed at providing a non-invasive treatment for DME, which currently affects approximately 37 million people globally and is expected to rise to 53 million by 2040 [4][6][8] - Licaminlimab is an anti-TNFα eye drop candidate that has shown positive effects in Phase 2 trials for DED, which impacts over 110 million people in G7 countries [9][11][12] - Privosegtor has demonstrated neuroprotective benefits in acute optic neuritis, a condition affecting up to 8 in 100,000 people worldwide, and has received orphan drug designation from both the FDA and EMA [13][15] Market Need - There is a significant unmet need for effective treatments for DME and DED, as current therapies often require invasive methods or do not adequately address patient needs [8][12]